- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
MR angio agent begins Phase II trials
Advanced Magnetics has begun the second phase of clinical testing on its MR angiography contrast agent. The product, called Code 7228, is the next technology scheduled for commercial development in the company's R&D pipeline. Early clinical data have
Advanced Magnetics has begun the second phase of clinical testing on its MR angiography contrast agent. The product, called Code 7228, is the next technology scheduled for commercial development in the company's R&D pipeline. Early clinical data have been encouraging, according to the company. Code 7228, a proprietary coated iron oxide compound, is being groomed for cardiovascular applications.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
